EN DE
Data-driven stock valuation

Alnylam Pharmaceuticals Inc (ALNY) fair value: what the stock is really worth

We calculate from audited financials what Alnylam Pharmaceuticals Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · US · Market cap $34.7B · ISIN US02043Q1076

At a glance

AP Alnylam Pharmaceuticals Inc logo Alnylam Pharmaceuticals Inc ALNY · US
Price$258.00
Fair Value$51.70
Upside−80.0%
Quality66/100

A solid business, but trading 399% above our fair value of $51.70.

As of Aug 20, 2026, the fair value of Alnylam Pharmaceuticals Inc is $51.70 per share against a price of $258.00, so the fair value sits 80% below the price. A model estimate from reported figures, not an analyst target.

✓Healthy Growth (revenue 5y +49.8 %/yr)
✓Solidly profitable · 12.6% net margin
✓Moderate debt · generates free cash flow
!Mixed vs. peers (7/14)
✓Wide moat 77/100
!Evidence only low, so the estimate is less certain
!The models disagree: range $38.77 to $141.93
Evidence: Low Range $38.77 to $141.93

Fair value as of: Aug 20, 2026

From 24 valuation models · updated 21 days ago

Share price +18.9% over the past month.

Watch Alnylam Pharmaceuticals Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case ($141.93). The favourable scenario is already priced in.
  • The model range is unusually wide ($38.77 to $141.93). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • Solid but not exceptional quality (66/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

$491.22 $120.42 Fair Value $51.70 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.

How to read this chart

60‑month range $120.42 – $491.22 · fair‑value band $38.77 – $141.93 · the $258.00 price screens above the $51.70 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Alnylam Pharmaceuticals Inc (ALNY) currently trades at $258.00, while our model-based Fair Value estimate is $51.70, implying the stock looks roughly 399.0% overvalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of $109.18 per share, and 0 of the 24 models we run sit above the $258.00 price. Bear case: the Economic Profit group reads lowest at $28.08, and 24 of the 24 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Alnylam Pharmaceuticals Inc generated revenue of $4.3B at a net margin of 12.6%. Revenue grew 96.4% year over year. It earns a return on equity of 90.4%. The balance sheet holds a net cash position of $379M. Fundamentals as of Aug 20, 2026

Scenario range: $38.77 (bear) to $141.93 (bull), the price of $258.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 48% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −80%, ALNY screens richer than that median.

Fair Value models

Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then ($2.60 per share) are deliberately not added.

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
EPV $37.07 $42.43 $47.13 74
FCF DCF $63.53 $97.18 $204.32 73
Growth DCF $60.04 $114.39 $203.44 73
All 24 models by family
DCF Models
FCF DCF $63.53 $97.18 $204.32 73
Owner Earnings $41.40 $88.00 $185.83 68
5Y Revenue Exit $48.59 $79.73 $144.83 68
5Y EBITDA Exit $54.02 $90.71 $162.63 70
5Y P/E Exit $50.21 $102.07 $172.06 66
10Y Revenue Exit $52.18 $106.82 $140.97 64
10Y EBITDA Exit $57.69 $118.52 $223.28 62
10Y P/E Exit $54.91 $110.31 $199.75 59
Earnings-Based
Graham-Dodd $15.98 $111.44 $156.39 61
Lynch FV $57.57 $82.25 $106.92 59
PEG = 1.0 $57.57 $82.25 $106.92 55
EPV $37.07 $42.43 $47.13 74
Multiples
P/E Multiple $38.77 $51.70 $64.62 63
P/S Multiple $29.96 $39.95 $49.94 58
P/B Multiple $19.95 $26.60 $33.25 55
EV/EBIT $52.76 $68.73 $84.70 66
EV/EBITDA $48.69 $63.30 $77.90 67
EV/Revenue $39.05 $53.70 $68.35 54
Asset-Based
NCAV (Graham) $2.96 $3.96 $5.91 54
Growth DCF
Growth DCF $60.04 $114.39 $203.44 73
Rev-Margin DCF $53.09 $90.51 $168.87 67
Economic Profit
Residual Income $18.98 $28.08 $360.10 61
ROIC Compounder $38.62 $46.50 $54.78 70
Growth Earnings
Growth-Adj P/E $76.42 $109.18 $141.93 65

Widest divergence: Growth Earnings ($109.18) versus Asset-Based ($3.96). Highest evidence: EPV (74).

Notify me when ALNY reaches fair value

Put ALNY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 64.8
P/S ratio 5.48 P/E × margin
EPS (TTM) $3.98 price ÷ EPS = P/E 64.8
Net margin 8.4% FY2025
Return on equity 90.4% TTM
Return on assets (EBIT) −8.6% avg 5y
More key figures
Profitability
Operating margin 23.0% TTM
Growth
Revenue (TTM) $4.3B TTM
Revenue growth (YoY) +96.4% 3y avg +53.0%
Balance sheet & cash flow
Free cash flow $465M FY2025
Net cash $379M FY2025

Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 66/100

Of which business quality 63 · Market factors (momentum, volatility) 25

Profitability 68
Margins and returns on capital today
Quality Growth 82
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 54
Balance sheet, leverage, solvency risk
Investment 70
Disciplined investing over empire-building
Low Volatility 61
Calm price path (market factor)
Momentum 15
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 36
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.

Full company description

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Alnylam Pharmaceuticals Inc reported revenue of $3.7B in FY2025 versus $844M in FY2021, a compound +44.8%/yr. Reported net income was $314M in FY2025.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
$3.7B
Latest YoY
+65.2%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+53.0%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+49.8%
Avg. revenue growth/yr (22Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+57.2%
EBIT margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−168.1% (2020) → 13.5% (2025)
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Revenue +44.8%/yr
FY21 $844M
FY22 $1.0B
FY23 $1.8B
FY24 $2.2B
FY25 $3.7B
Net income
FY21 −$853M
FY22 −$1.1B
FY23 −$440M
FY24 −$278M
FY25 $314M

ALNY screens 399% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Alnylam Pharmaceuticals Inc · Fair Value
$51.70 −399%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Alnylam Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/ALNY

Recent news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Biotechnology · 633 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 66 · Top 25%
Fair Value upside −81% · Bottom 25%
Profitability
Return on equity (TTM) 90% · Top 25%
Return on assets 10% · Top 25%
Net margin (TTM) 13% · Top 25%
Operating margin (TTM) 23% · Top 25%
Growth and dividend
Revenue growth 96% · Top 25%
Balance sheet
Debt / equity 1.28× · Highest 25%

Valuation Multiples vs Biotechnology median · lower = cheaper

P/E (TTM) 64.8× · Priciest 25%
P/B 45.25× · Priciest 25%
P/S (TTM) 8.33× · Pricier than median
P/FCF 76.7× · Priciest 25%
EV/EBITDA 43.5× · Priciest 25%
PEG 0.51× · Cheapest 25%

What the price implies (reverse DCF)

The inverse question: what free-cash-flow growth must Alnylam Pharmaceuticals Inc deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.

Implied FCF growth, 10 years+20.8 % per year
Achieved revenue growth, 5 years+49.8 % p.a.
Sector median revenue growth+4.4 %
FCF yield on price1.34 %
Discount rate (WACC) in the models8.1 %

The price demands less growth than the company recently delivered: even a weaker business would justify the price. Ranking of the largest stocks →

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 0
PAST100 · sector 0
HEALTH36 · sector 98
DIVIDEND0 · sector 25

VALUE 0: the price sits above our fair-value range.

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $546.12 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $827.72 $594.40 −28%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,452,000 KRW 1,055,793 KRW −27%
CSL Limited CSL A$174.50 A$141.68 −19%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE 22UA €80.60 €52.92 −34%
Incyte Corporation INCY $123.22 $115.79 −6%

Compare Alnylam Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Alnylam Pharmaceuticals Inc (ALNY) overvalued or undervalued?
As of Aug 20, 2026, our model estimates a fair value of $51.70 versus a price of $258.00, about −80% upside (overvalued).
What is the fair value of ALNY?
Our model-based fair value for Alnylam Pharmaceuticals Inc is $51.70 (as of Aug 20, 2026), built from audited fundamentals. The current price: $258.00.
What is the quality score of ALNY?
Alnylam Pharmaceuticals Inc has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alnylam Pharmaceuticals Inc (ALNY)?
Our model-based price target is the fair value of $51.70 (as of Aug 20, 2026) from 24 valuation models. Cautious scenario $38.77, optimistic scenario $141.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Alnylam Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $51.70, about −80% upside versus a price of $258.00 (overvalued). Cautious scenario $38.77, optimistic scenario $141.93. The calculation is refreshed regularly with new filings.
What is the revenue of Alnylam Pharmaceuticals Inc (ALNY)?
Alnylam Pharmaceuticals Inc reported trailing-twelve-month revenue of about $4.3B (latest available figure, as of Aug 20, 2026).
What is the net profit margin of ALNY?
The net profit margin of Alnylam Pharmaceuticals Inc is about 12.6%, meaning it keeps roughly 12.6% of revenue as net income. Based on the latest reported figures.
What growth is priced into Alnylam Pharmaceuticals Inc (ALNY)?
For today's price to be fair in a discounted-cash-flow model, Alnylam Pharmaceuticals Inc would have to grow free cash flow by +20.8 % per year for ten years (discount rate 8.1 %, then 2 % perpetual growth). Over the last 5 years revenue grew +49.8 % per year. As of Aug 20, 2026.
What discount rate (WACC) does the fair value of ALNY use?
Our models discount Alnylam Pharmaceuticals Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.30, country premium for USA. The same rate applies in all 26 models.
What is the intrinsic value of Alnylam Pharmaceuticals Inc (ALNY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alnylam Pharmaceuticals Inc it is $51.70 per share (as of Aug 20, 2026), against a price of $258.00. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Alnylam Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Aug 20, 2026, ALNY trades above its calculated fair value: price $258.00, fair value $51.70, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALNY?
No. The price is what the market pays today ($258.00); the fair value is what the company's own numbers justify ($51.70). For Alnylam Pharmaceuticals Inc the two are $206.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alnylam Pharmaceuticals Inc worth?
The market values Alnylam Pharmaceuticals Inc at about $34.7B (market capitalisation, as of Aug 20, 2026). Per share that is $258.00; our models calculate a fair value of $51.70 per share.
What do the bullish and bearish scenarios say about ALNY?
Our models span a range for Alnylam Pharmaceuticals Inc: cautious scenario $38.77, base $51.70, optimistic $141.93 per share (as of Aug 20, 2026, price $258.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALNY?
Alnylam Pharmaceuticals Inc trades at a price-to-earnings ratio of 64.8 (as of Aug 20, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $51.70 is built from several models across several years. Other multiples: PEG 0.5, P/B 45.3, P/S 8.3, EV/EBITDA 43.5.
What is the PEG ratio of ALNY?
The PEG ratio of Alnylam Pharmaceuticals Inc is 0.51 (P/E divided by earnings growth, as of Aug 20, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Alnylam Pharmaceuticals Inc (ALNY)?
Balance-sheet figures for Alnylam Pharmaceuticals Inc (as of Aug 20, 2026): return on equity 90.4%, debt of 1.28 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is ALNY from its 52-week high?
Alnylam Pharmaceuticals Inc trades at $258.00, about 48% below its 52-week high of $495.55 (as of Aug 20, 2026). Distance from the high says nothing about value: that is what the fair value of $51.70 is for.
Which stocks are comparable to Alnylam Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alnylam Pharmaceuticals Inc stock attractive at the current price?
The data as of Aug 20, 2026: price $258.00, calculated fair value $51.70 (−80%), Quality Score 66/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALNY calculated?
We run Alnylam Pharmaceuticals Inc through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $51.70, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed

Watch Alnylam Pharmaceuticals Inc in the live analysis

One click puts Alnylam Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.